surmount-1 tirzepatide trial obesity without diabetes ๐ Could a new medication help reduce complications of obesity? The SURMOUNT-MMO investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but diabetes. Researchers SURPASS to SURMOUNT: The Tirzepatide
Pay in 4 interest-free payments of $5.96 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 23 - Aug 28























